Effect of Preoperative Budesonide Inhalation on Arterial Blood Oxygenation and Intrapulmonary Shunt During OLV
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03394222 |
|
Recruitment Status :
Completed
First Posted : January 9, 2018
Last Update Posted : January 9, 2018
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Lung Cancer | Drug: preoperative budesonide inhalation Drug: preoperative normal saline inhalation | Phase 4 |
Population:
The target population comprises all adult aged 45-65 years who was diagnosed lung cancer and to receive video-assist thoracoscopic lobectomy under general anethesia.The study sample will include 50 subjects of both gender and any race or ethnicity.
Procedures:
Eligible and consented patients will be enrolled into the study if all eligibility criteria are met and will be randomly allocated to one of the two study arms:Budesonide inhalation group vs Normal saline inhalation group
Study Duration:
Overall duration of the study is 10 months.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 50 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Care Provider) |
| Masking Description: | One research assistant was tasked to give the interventional medication in indentical containers to the anesthesiologists(care provider) in charge of the participants for preoperative preparations.Both the participants and care providers were blinded. |
| Primary Purpose: | Supportive Care |
| Official Title: | Effect of Preoperative Budesonide Inhalation on Arterial Blood Oxygenation and Intrapulmonary Shunt in Patients Received One-lung Ventilation |
| Actual Study Start Date : | July 2016 |
| Actual Primary Completion Date : | March 2017 |
| Actual Study Completion Date : | April 2017 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Budesonide inhalation group
This group of participants were to receive 2mg/4ml of preoperative budesonide inhalation (Khartoum Road NORTH RYDE NSW 2113 Australia. AstraZeneca Pty Ltd) for 10 to 15min.
|
Drug: preoperative budesonide inhalation |
|
Placebo Comparator: Normal saline inhalation group
This group of participants were to receive4ml of preoperative normal saline inhalation for 10 to 15min.
|
Drug: preoperative normal saline inhalation |
- Arterial blood oxygenation [ Time Frame: Arterial blood oxygenation was assessed through blood gas analysis before intervention,before OLV ,10 min after OLV,30 min after OLV,60 min after OLV and 10min after two-lung ventilation. ]Arterial blood oxygenation was assessed through blood gas analysis of sample taken from radial artery
- Intrapulmonary shunt [ Time Frame: Intrapulmonary shunt was assessed through blood gas analysis before intervention,before OLV ,10 min after OLV,30 min after OLV,60 min after OLV and 10min after two-lung ventilation ]Intrapulmonary shunt was assessed through blood gas analysis of sample taken
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 45 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Aged 45 yr to 65 yr ,height 155-176cm,weight 45-75kg,body mass index(BMI)18-27kg/m2,ASA Physical Status Classifications I to II,left-lateral position during OLV ,normal cardiac and pulmonary function ,and no cardiac,hepatic,renal and endocrine diseases.Diagnosed with uncomplicated lung cancer and was to receive video-assist thoracoscopic lobectomy under general anesthesia.
Exclusion Criteria:
- FEV1/FVC<70%,asthma,chronic obstructive pulmonary disease,acute lung infection,past history of thoracic surgery. preoperative glucocorticoid medication,preoperative chemotherapy,SpO2 kept below 90% for more than 15 minutes during operation,blood transfusion during operation,OLV less than an hour,occurrence of severe complications like allergic shock.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03394222
| Principal Investigator: | Wenhua chen, M.D. | Fujian Medical University Union Hospital |
| Responsible Party: | Fujian Medical University Union Hospital |
| ClinicalTrials.gov Identifier: | NCT03394222 |
| Other Study ID Numbers: |
FujianUnionAnethesia |
| First Posted: | January 9, 2018 Key Record Dates |
| Last Update Posted: | January 9, 2018 |
| Last Verified: | January 2018 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Respiratory Aspiration Respiration Disorders Respiratory Tract Diseases Pathologic Processes Budesonide Anti-Inflammatory Agents Bronchodilator Agents Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists |

